---
reference_id: "PMID:41113075"
title: "Spontaneous colonic transection following pathologic complete response to pembrolizumab in high microsatellite instability colorectal cancer: A case report and review of literature."
authors:
- Lee C
- Kim MH
- Choi ET
- Park IJ
- Lim SB
- Yoon YS
- Kim CW
- Lee JL
- Park EJ
journal: World J Clin Cases
year: '2025'
doi: 10.12998/wjcc.v13.i30.110330
content_type: abstract_only
---

# Spontaneous colonic transection following pathologic complete response to pembrolizumab in high microsatellite instability colorectal cancer: A case report and review of literature.
**Authors:** Lee C, Kim MH, Choi ET, Park IJ, Lim SB, Yoon YS, Kim CW, Lee JL, Park EJ
**Journal:** World J Clin Cases (2025)
**DOI:** [10.12998/wjcc.v13.i30.110330](https://doi.org/10.12998/wjcc.v13.i30.110330)

## Content

1. World J Clin Cases. 2025 Oct 26;13(30):110330. doi: 
10.12998/wjcc.v13.i30.110330.

Spontaneous colonic transection following pathologic complete response to 
pembrolizumab in high microsatellite instability colorectal cancer: A case 
report and review of literature.

Lee C(1), Kim MH(2), Choi ET(3), Park IJ(1), Lim SB(1), Yoon YS(1), Kim CW(1), 
Lee JL(1), Park EJ(1).

Author information:
(1)Division of Colon and Rectal Surgery, Department of Surgery, University of 
Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea.
(2)Division of Colon and Rectal Surgery, Department of Surgery, University of 
Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea. 
mhjerrykim@gmail.com.
(3)Department of Nursing, Asan Medical Center, Seoul 05505, South Korea.

BACKGROUND: High microsatellite instability (MSI-H) colorectal cancer (CRC), 
caused by deficient mismatch repair, accounts for about 15% of all CRC cases and 
is more common in right-sided tumors. While early-stage MSI-H CRC has a 
relatively good prognosis, advanced cases often respond poorly to standard 
chemotherapy. Immune checkpoint inhibitors, such as pembrolizumab, have shown 
strong and lasting effects in MSI-H CRC. Pembrolizumab is now approved as a 
first-line treatment for metastatic MSI-H CRC due to its superior outcomes 
compared to traditional chemotherapy.
CASE SUMMARY: A 44-year-old male with MSI-H transverse colon cancer presented 
with hematochezia, abdominal pain, and significant weight loss. Imaging revealed 
a bulky tumor with invasion of adjacent structures and multiple liver lesions. A 
diverting ileostomy was performed followed by 36 cycles of pembrolizumab. The 
patient achieved a clinical and radiologic complete response. One month after 
completing the treatment, the patient underwent laparoscopic right 
hemicolectomy. A spontaneous transection of the colon at the original tumor site 
was unexpectedly identified. Final pathology confirmed pathological complete 
response (ypT0N0) with fibrosis. The patient recovered well after surgery, and 
follow-up showed no evidence of recurrence.
CONCLUSION: Immune checkpoint inhibitors may cause delayed structural damage to 
bowel tissue even after apparent complete tumor regression.

Â©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights 
reserved.

DOI: 10.12998/wjcc.v13.i30.110330
PMCID: PMC12531674
PMID: 41113075

Conflict of interest statement: Conflict-of-interest statement: All authors 
declare no conflicts of interest.